A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Autoantibodies
/ blood
Case-Control Studies
Data Accuracy
Dermatomyositis
/ blood
Diagnostic Tests, Routine
/ methods
Enzyme-Linked Immunosorbent Assay
/ methods
False Negative Reactions
Humans
Immunoblotting
/ methods
Immunoprecipitation
/ methods
Sensitivity and Specificity
Serologic Tests
/ methods
Transcription Factors
/ immunology
ELISA - enzyme-linked immunosorbent assay
TIF1γ
autoantibodies
cancer
dermatomysitis
myositis
myositis - diagnosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
10
2021
accepted:
12
01
2022
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
16
3
2022
Statut:
epublish
Résumé
Anti-TIF1γ is an important autoantibody in the diagnosis of cancer-associated dermatomyositis and the most common autoantibody in juvenile onset dermatomyositis. Its reliable detection is important to instigate further investigations into underlying malignancy in adults. We previously showed that commercial assays using line and dot blots do not reliably detect anti-TIF1γ. We aimed to test a new commercial ELISA and compare with previously obtained protein immunoprecipitation. Radio-labelled immunoprecipitation had previously been used to determine the autoantibody status of patients with immune-mediated inflammatory myopathies and several healthy controls. ELISA was undertaken on healthy control and anti-TIF1γ sera and compared to previous immunoprecipitation data. A total of 110 serum samples were analysed: 42 myositis patients with anti- TIF1γ and 68 autoantibody negative healthy control sera. Anti-TIF1γ was detected by ELISA in 41 out of 42 of the anti-TIF1γ-positive samples by immunoprecipitation, and in none of the healthy controls, giving a sensitivity of 97.6% and specificity of 100%. The false negative rate was 2%. ELISA is an affordable and time-efficient method which is accurate in detecting anti-TIF1γ.
Identifiants
pubmed: 35154119
doi: 10.3389/fimmu.2022.804037
pmc: PMC8831764
doi:
Substances chimiques
Autoantibodies
0
TRIM33 protein, human
0
Transcription Factors
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
804037Informations de copyright
Copyright © 2022 Mulhearn, Li, McMorrow, Lu, McHugh and Tansley.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Rheum Dis. 2019 Jun;78(6):858-860
pubmed: 30760469
Neurology. 2016 Jul 19;87(3):299-308
pubmed: 27343066
Arthritis Rheum. 2013 Nov;65(11):2954-62
pubmed: 24037894
Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1048-1051
pubmed: 31376258
J Dermatol Sci. 2016 Dec;84(3):272-281
pubmed: 27693019
Rheumatology (Oxford). 2020 Aug 1;59(8):2109-2114
pubmed: 32030410
Nat Rev Rheumatol. 2018 Apr 20;14(5):290-302
pubmed: 29674612
J Autoimmun. 2017 Nov;84:55-64
pubmed: 28663002
J Autoimmun. 2019 Jul;101:48-55
pubmed: 30992170
Arthritis Rheum. 2006 Nov;54(11):3682-9
pubmed: 17075819
Rheumatology (Oxford). 2019 Apr 1;58(4):650-655
pubmed: 30535395
Front Immunol. 2017 Aug 21;8:992
pubmed: 28871260
Arthritis Rheum. 2012 Feb;64(2):513-22
pubmed: 21987216